Management of febrile neutropenia in adult cancer patients: a practical step-by-step guide for emergency and clinical practice Artykuł przeglądowy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Febrile neutropenia is a life-threatening oncological emergency requiring immediate evaluation and treatment. Rapid recognition, risk stratification, and empiric antimicrobial administration within the first hour (the golden hour) are essential to lower mortality. This practical guide presents a streamlined framework for managing adult cancer patients with febrile neutropenia. We discuss diagnostic work-up, risk assessment via MASCC and CISNE scores, empiric antibiotic selection, criteria for outpatient care, and therapeutic use of granulocyte colony-stimulating factors.
##plugins.generic.usageStats.downloads##
##plugins.themes.bootstrap3.article.details##
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: ? Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
2. Klastersky J, de Naurois J, Rolston K et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(suppl 5): v111-8. https://doi.org/10.1093/annonc/mdw325.
3. Kuderer NM, Dale DC, Crawford J et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106(10): 2258-66. https://doi.org/10.1002/cncr.21847.
4. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52(4): e56-93. https://doi.org/10.1093/cid/cir073.
5. Maertens JA, Raad II, Marr KA et al. Isavuconazole versus caspofungin in patients with acute myelogenous leukemia or myelodysplastic syndrome and febrile neutropenia. Haematologica. 2021; 106(12): 3100-9. https://doi.org/10.3324/haematol.2020.274191.
6. Zimmer AJ, Freifeld AG. Optimal Antimicrobial Management of Febrile Neutropenia. Curr Infect Dis Rep. 2019; 21(3): 11. https://doi.org/10.1007/s11908-019-0668-3.
7. Coyne CJ, Le V, Brennan JJ et al. Application of the MASCC and CISNE Risk Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department. Ann Emerg Med. 2017; 69(6): 755-64. https://doi.org/10.1016/j.annemergmed.2016.11.009.
8. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18(16): 3038-51. https://doi.org/10.1200/JCO.2000.18.16.3038.
9. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the Spanish Society of Medical Oncology (SEOM). J Clin Oncol. 2015; 33(5): 465-71. https://doi.org/10.1200/JCO.2014.57.2347.
10. Sung L, Robinson PD, Lehrnbecher T et al. Guideline for the Management of Fever and Neutropenia in Children with Cancer and Hematopoietic Stem Cell Transplantation: 2017 Update. J Clin Oncol. 2017; 35(18): 2082-90. https://doi.org/10.1200/JCO.2016.71.0434.
11. Paul M, Yahav D, Bivas A et al. Anti-Gram-positive coverage for febrile neutropenic cancer patients. Cochrane Database Syst Rev. 2012; (10): CD003894. https://doi.org/10.1002/14651858.CD003894.pub3.
12. Smith TJ, Bohlke K, Lyman GH et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33(28): 3199-212. https://doi.org/10.1200/JCO.2015.62.3488.
13. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011; 47(1): 8-32. https://doi.org/10.1016/j.ejca.2010.10.013.
14. Mhaskar R, Clark O, Lyman G et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014; (10): CD003039. https://doi.org/10.1002/14651858.CD003039.pub2.